You just read:

Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia

News provided by

Braeburn Pharmaceuticals

26 Apr, 2017, 13:55 ET